Today is

Department of

Obstetrics and Gynecology

Photo of  Thomas Herzog, MD

Thomas Herzog, MD

Clinical Director University of Cincinnati Cancer Institute and Professor, Obstetrics and Gynecology, UC College of Medicine

Education/Credentials
  • MD: University of Cincinnati College of Medicine
  • BA: Miami University

Board Certifications & Licenses
  • American Board of Obstetrics & Gynecology- Ohio, 1988
  • American Board of Obstetrics & Gynecology - Missouri, 1990
  • American Board of Obstetrics & Gynecology - New York, 2004
Contact Information
  • University of Cincinnati Cancer Institute
  • 3255 Eden Avenue, Suite 250B
  • Cincinnati, Ohio 45019
  • Office 513-558-2177
  • Fax 513-558-2666
  • Email thomas.herzog@uc.edu

Peer Reviewed Publications

Display All

Baumann K.; Calvert P.; Canzler U.; Colombo N.; Crescenzo R.; Del Campo J.; Diaz-Padilla I.; Du Bois A.; Floquet A.; Friedlander M.; Fujiwara K.; Harter P.; Herzog T.; Kim B.; Kim J.; Kimmig R.; Kurzeder C.; Lesoin A.; Marth C.; Mirza M.; Mitrica I.; Monk B.; Mouret-Reynier M.; Pignata S.; Pujade-Lauraine E.; Rau J.; Ray-Coquard I.; Scambia G.; Schade-Brittinger C.; Shimada M.; Vasey P.; Vergote I.; Wang Q.; Zang R. 10-20-2014. Incorporation of pazopanib in maintenance therapy of ovarian cancer Journal of Clinical Oncology, 32 30, 3374-3381

Alvarez R.; Armstrong D.; Coleman R.; Herzog T.; Monk B. 05-01-2015. In assessing surrogate clinical trial end points: Drug safety is a requisite Journal of Clinical Oncology, 33 13, 1511-1512

Barrett C.; Bois A.; Calvert P.; Campo J.; Colombo N.; Crescenzo R.; Fiane B.; Floquet A.; Friedlander M.; Herzog T.; Isonishin S.; Kim J.; Meier W.; Mitrica I.; Monk B.; Pisano C.; Reinthaller A.; Vergote I.; Wang K. 01-01-2015. Progression-free survival by local investigator versus independent central review: Comparative analy Gynecologic Oncology, 136 1, 37-42

Brower S.; Coleman R.; Herzog T.; Krivak T.; Leath C.; Previs R.; Secord A.; Tian C. 01-01-2015. Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian ca Gynecologic Oncology, 138 2, 267-271

Eisenhauer E.; Herzog T.; Jackson A. 01-01-2015. Emerging therapies: Angiogenesis inhibitors for ovarian cancer Expert Opinion on Emerging Drugs, 20 2, 331-346

Akerley W.; Berek J.; Demars L.; Edwards R.; Friccius-Quecke H.; Herzog T.; Holloway R.; Krasner C.; Lentz S.; Method M.; Morris R.; Parker L.; Plaxe S.; Walker J. 01-01-2014. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian International Journal of Gynecological Cancer, 24 9, 1583-1589

Ananth C.; Burke W.; Glied S.; Hershman D.; Herzog T.; Lu Y.; Neugut A.; Tsui J.; Wright J. 01-01-2014. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer Cancer, 120 8, 1246-1254

Bell M.; Braly P.; Childs B.; Drake R.; Einstein M.; Herzog T.; Hines J.; Monk B.; Roman L.; Rose P.; Secord A.; Wenham R. 01-01-2014. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer Gynecologic Oncology, 132 3, 517-525

Boruta D.; Brewer M.; Burke W.; Gehrig P.; Herzog T.; Leitao M.; Olawaiye A.; Orr J.; Salom E.; Shahin F.; Villella J. 01-01-2014. Corrigendum to "Endometrial cancer: A review and current management strategies: Part I" [Gynecol Onc Gynecologic Oncology, 135 3, 625